| Name | Title | Contact Details |
|---|
Supporting IVD innovators with RA/QA/CRO, FDA/CE IVD Submission, Training, Go-to-Market support and more.
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes
Amalgam Rx develops digital therapies that empower patients with chronic diseases to achieve better outcomes
Elligo Health Research helps speed new therapies to market by providing large numbers of patients and clinicians the opportunity to participate in clinical research. Elligo enables rapid and effective clinical trial enrollment and facilitates the study site operations so that clinicians can focus on their research. Our unique direct to patient model allows us to streamline patient identification and qualification, site activation, patient enrollment, study initiation and study conclusion for more efficient and cost-effective trials.
Md's Choice Inc is a Louisville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.